Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
05/2005
05/11/2005CN1615316A Novel immunogenic mimetics of multimer proteins
05/11/2005CN1615315A Tumor specific monoclonal antibodies
05/11/2005CN1615140A Polynucleotide therapy
05/11/2005CN1614030A Gene artificial synthesis and SARS virus protective antigen-amino acid series
05/11/2005CN1614011A Technology for closed double-circulating column chromatographing purifying inactivated virus vaccine
05/11/2005CN1613874A Human tumour necrosin antibody, its preparation and medicinal composition
05/11/2005CN1613870A Tetramer combined with SARS antigen peptide and its preparation and use
05/11/2005CN1613503A Technology for producing viral vaccine in biological reactor
05/11/2005CN1613348A Forage additive containing trace arsanilic acid
05/11/2005CN1201005C Antigen binding fragments that specifically detect cancer cells, nucleotindes encoding the fragments, and use thereof for the prophylaxis and detection of cancers
05/11/2005CN1201004C HER-2/neu fusion proteins
05/11/2005CN1200734C Treatment of refractory human tumors with epidermal growth factor receptor antagonists
05/11/2005CN1200733C Reversal of viral-induced systemic shock and respiratory distress by blockade of lymphotoxin beta pathway
05/11/2005CN1200732C Hepatitis B vaccine with lactic acid-ethanediol copolymer as adjuvant
05/11/2005CN1200731C Derivatives of pneumococcal choline binding proteins for vaccines
05/11/2005CN1200730C Pneumococcal and Meningococcal vaccines formulated with interleukin-12
05/10/2005US6891037 Method for the isolation of polysaccharides
05/10/2005US6891028 Nucleic acids encoding transferrin receptor-like proteins
05/10/2005US6891023 Antibodies and Fv fragment recognizing antigen IOR C2
05/10/2005US6890949 Amino ceramide-like compounds and therapeutic methods of use
05/10/2005US6890938 Antiinflammatory agents
05/10/2005US6890924 Substituted bicyclic derivatives for the treatment of abnormal cell growth
05/10/2005US6890899 A lipolytic or lipid mobilising factor (LMF) produced by the cachexia-inducing murine tumor MAC16; weight reduction or controlling obesity; administering a Zn-alpha 2-glycoprotein
05/10/2005US6890751 NRG-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
05/10/2005US6890737 For prognosing/monitoring efficiency of treatment of chronic hepatitis/natural disease; genetic engineering
05/10/2005US6890554 Genetic immunization with cationic lipids
05/10/2005US6890542 The use of a live mutant Leishmania in the preparation of a vaccine and to vaccine formulations for use in immunising mammals, such as dogs and/or humans. The mutant Leishmania comprises at least one defective cysteine proteinase gene.
05/10/2005US6890540 Vaccine formulation
05/10/2005US6890539 Peptide encoded by gene identified herein as pho2-2, obtainable from Group B Streptococcus, or a homologue or a functional fragment thereof; neonatal infections, urinary tract infections
05/10/2005US6890538 Immunization against herpes simplex virus
05/10/2005US6890535 Pharmaceutical compositions and methods for treatment of amyloid diseases
05/10/2005US6890534 Aiolos genes and polypeptides of the present invention are useful for studying, diagnosing and/or treating diseases associated with unwanted cell proliferation, e.g., leukemias or lymphomas
05/10/2005US6890532 Postexposure prophylaxis therapy
05/10/2005US6890527 Methods of treatment
05/10/2005US6890515 Non-invasive localization of a light-emitting conjugate in a mammal
05/10/2005CA2378862C Multi-component vaccine to protect against disease caused by haemophilus influenzae and moraxella catarrhalis
05/10/2005CA2330935C A mutant human hepatitis b viral strain and uses thereof
05/10/2005CA2123579C Recombinant multivalent m protein vaccine
05/10/2005CA1341482C Process for preparing fragments of aids-associated retroviruses
05/06/2005WO2005040418A2 Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (r-spondins) and/or wnt
05/06/2005WO2005040390A1 A recombinant vaccine using yellow fever virus as vector
05/06/2005WO2005040365A1 Immunogenic composition and method of developing a vaccine based on portions of the hiv matrix protein
05/06/2005WO2005040353A2 Immunogenic compostion and method of developing a vaccine based on psoralen inactivated hiv
05/06/2005WO2005040352A2 Immunogenic composition and method of developing a vaccine based on factor h binding sites
05/06/2005WO2005040351A2 Compositions for inducing cell growth and differentiation and methods of using same
05/06/2005WO2005040349A2 Immunogenic composition and method of developing a vaccine based on cyclophilin a binding site
05/06/2005WO2005040347A2 Methods and compositions for inhibiting cell growth and proliferation
05/06/2005WO2005040338A2 Constrained alkaloid immunogens and antibodies and uses thereof
05/06/2005WO2005040219A1 Laminin-5 gamma2-binding peptides, related compositions, and use thereof
05/06/2005WO2005040218A1 METHOD FOR PREPARING COMPOSITE IgY SPECIFIC AGAINST PERIODONTAL DISEASE AND COMPOSITE PREPARATION THEREOF
05/06/2005WO2005040206A1 Glurp-msp3 fusion protein, immunogenic compositions and malarial vaccines containing it
05/06/2005WO2005040203A2 Msp-3-like family of genes
05/06/2005WO2005039634A1 Vaccine compositions comprising an interleukin 18 and saponin adjuvant system
05/06/2005WO2005039633A1 Agent for treating leishmania infections
05/06/2005WO2005039632A1 Colorectal cancer antigen
05/06/2005WO2005039631A1 Vaccines containing the hiv tat protein as an adjuvant for the enhancement of cytotoxic t-cell responses
05/06/2005WO2005039630A2 Immunogenic compositions
05/06/2005WO2005039615A1 Use of caspase-8 inhibitors for modulating hematopoiesis
05/06/2005WO2005039501A2 Immunogenic composition and method of developing a vaccine based on fusion protein
05/06/2005WO2005039393A2 Techniques to treat neurological disorders by attenuating the production of pro-inflammatory mediators
05/06/2005WO2005021033A3 Vaccine
05/06/2005WO2005021031A3 Live attenuated bacterial vaccine
05/06/2005WO2005014041A3 Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases
05/06/2005WO2005005467A3 Novel immune booster compound comprising an ef adenoviral sequence
05/06/2005WO2005003775A3 Glycoconjugates and their use as potential vaccines against infection by shigella flexneri
05/06/2005WO2005002502A3 An assay for detecting the presence of processing inhibitory antibodies against the apical membrane antigene-1 of plasmodium falciparum in biological samples
05/06/2005WO2005000223A3 Method of treating retinopathies and disorders associated with blood vessel loss
05/06/2005WO2004112825A3 Combinations of tumor-associated antigens for the treatment of various types of cancers
05/06/2005WO2004112482A8 Biological active coating components, coatings, and coated surfaces
05/06/2005WO2004110345A8 Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
05/06/2005WO2004094644A3 Vibrio cholerae proteins expressed during infection
05/06/2005WO2004080419A3 Humanized antibodies that recognize beta amyloid peptide
05/06/2005WO2004078949A3 Genes of an otitis media isolate of nontypeable haemophilus influenzae
05/06/2005WO2004078776A3 Ny-eso-1 peptides which bind to class ii molecules and uses thereof
05/06/2005WO2004071529A3 Uses of anti-insulin-like growth factor i receptor antibodies
05/06/2005WO2004059318A3 Methods of detecting the inhibition of fibrocyte formation and methods and compositions for enhancing fibrocyte formation
05/06/2005WO2004053086A3 Plasmodium falciparum antigens and methods of use
05/06/2005WO2004052933B1 Peptide oligomers for use as hiv vaccines
05/06/2005WO2004044220A3 Flaviviris fusion inhibitors
05/06/2005WO2003072607A8 Monoclonal antibodies that are cross-reactive against bacterial collagen binding proteins
05/06/2005WO2003068146A3 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
05/06/2005CA2543779A1 Techniques to treat neurological disorders by attenuating the production of pro-inflammatory mediators
05/06/2005CA2543565A1 Use of caspase-8 inhibitors for modulating hematopoiesis
05/06/2005CA2542928A1 Use of metallic cations to improve functional activity of antibodies
05/06/2005CA2542924A1 Msp-3-like family of genes
05/06/2005CA2542881A1 Antibody with an optimized fucose content/galactose content ratio
05/06/2005CA2542686A1 Colorectal cancer antigen
05/06/2005CA2542239A1 Multispecific deimmunized cd3-binders
05/06/2005CA2542221A1 Vaccine for periodontal disease
05/06/2005CA2542175A1 Vaccines containing the hiv tat protein as an adjuvant for the enhancement of cytotoxic t-cell responses
05/06/2005CA2541868A1 Antibodies having a mutated amino acid residue at position 268 (ch2 region) in constant regions
05/06/2005CA2541695A1 Vaccine compositions comprising an interleukin 18 and saponin adjuvant system
05/06/2005CA2541693A1 Immunogenic compositions
05/06/2005CA2541511A1 Immunogenic composition and method of developing a vaccine based on portions of the hiv matrix protein
05/06/2005CA2541506A1 Immunogenic compostion and method of developing a vaccine based on psoralen inactivated hiv
05/06/2005CA2541501A1 Immunogenic composition and method of developing a vaccine based on factor h binding sites
05/06/2005CA2541497A1 Immunogenic composition and method of developing a vaccine based on cyclophilin a binding site
05/06/2005CA2541492A1 Immunogenic composition and method of developing a vaccine based on fusion protein
05/05/2005US20050096484 Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
05/05/2005US20050096460 Beta-amyloid peptide-binding proteins and polynucleotides encoding the same
1 ... 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 ... 1823